Epstein-Barr virus (EBV) associated lymphoproliferative diseases (LPDs) cover a wide range of lymphocytes disorders spanning B, T, and NK cells. The classification of Epstein-Barr virus (EBV) associated lymphoproliferative disease (LPD) is evolving. We report a 63-year-old male patient with EBV-associated T/B cell LPD diagnosed by pathological biopsy of lymph nodes, which is a new type of EBV-associated LPD has not been reported previously. Because of its rarity, standard treatment has not been established.
However, to our best knowledge, EBV-associated T/B cell lymphoproliferative disease has not been reported previously. Here, we report a rare case of EBV-associated T/B cell LPD successfully treated with R-CVP (rituximab, cyclophosphamide, vindesine and prednisone). 
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DISCUSSION
To our knowledge, this is the first report of a patient with EBV-associated T/B cell LPD in long-term CR following R-CVP therapy, with no use of high-dose chemoradiotherapy in combination with hematologic stem-cell transplantation.
Therapeutic approaches on EBV-associated LPD include high-dose immunoglobulin, IL-2, antiviral agents, IFN-αorIFN-γ, corticosteroids, rituximab, hematopoieticstem-cell transplantation and EBV specific T cells4.But these therapies generally have not been successful and relapses were common. Here we report a rare case with EBV-associated T/B cell LPD, which is a new type of EBV-associated LPD has not been reported previously.Because of its rarity, standard treatment has not been established.
Rituximab is a chimeric mouse/human monoclonal antibody that specifically targets the CD20 antigen on the surface of normal and malignant human B cells, which has been widely used in B cell lymphomas5,6.Rituximab in combination with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) has already improved survival in elderly patients with aggressive non-Hodgkin's lymphoma7. In terms of its safety and efficacy, our case provided an evidence supporting the use of rituximab and chemotherapy combination in EBV-associated T/B cell LPD treatment.
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